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Summary
Background: Dyspnea represents a very frequent and distress-
ing symptom in patients with advanced cancer. This study was
undertaken to assess the efficacy of morphine on dyspnea and
its safety for ventilatory function in elderly advanced cancer
patients.
Patients and methods: Nine elderly patients with dyspnea
due to lung involvement were randomized to receive either
morphine subcutaneously (5 mg in seven opioid-nai've patients
and 3.75 mg in two patients on top of their regular oral dose of
7.5 mg q4h) or placebo on day 1. On day 2, they were crossed
over to receive the alternate treatment. Dyspnea was assessed
every fifteen minutes using a visual analogue scale (VAS: 0-100
mm) and the ordinal scale developed by Borg (0-10 points).
Pain, somnolence and anxiety were assessed using VAS. Respi-
ratory effort, respiratory rate and oxygen saturation were also
measured repeatly.
Results: Mean changes in dyspnea 45 minutes after injec-
tion were -25 ± 10 mm and -1.2 ± 1.2 points for morphine,
versus 0.6 ± 7.7 mm (f < 0.01) and -0.1 ± 0.3 points (P = 0.03)
for placebo on VAS and Borg scale, respectively. No relevant
changes were observed in somnolence, pain, anxiety, respira-
tory effort and rate, and oxygen saturation.
Conclusions: Morphine appears effective for cancer dyspnea,
and it does not compromise respiratory function at the dose
level used.
Key words: dyspnea, morphine, terminal cancer, ventilatory
function
Introduction
Dyspnea represents a frequent and distressing symptom
in patients with advanced cancer [1, 2]. The most fre-
quent cause is the presence of lung involvement by
primary or metastatic tumor [2]. In recent years, a
number of drugs have been proposed for decreasing the
sensation of dyspnea. Benzodiazepines have been found
to exert contradictory effects on the dyspnea of both
chronic pulmonary disease and cancer [3-6]. On the
other hand, opioids have been suggested to be beneficial
in decreasing the intensity of dyspnea without signifi-
cantly altering the respiratory drive [7-9]. However, only
one randomized double blind controlled trial has been
published on the efficacy of morphine in patients with
cancer dyspnea [8]. This study has been conducted in
10 patients with restrictive dyspnea due to progressive
cancer.
Since dyspnea tends to vary dramatically from one
moment to the other, and is frequently accompanied by
other devastating symptoms like delirium, randomized
control trials are extremely difficult to conduct in pa-
tients with severe cancer dyspnea at rest [9]. Hence the
studies of pharmacological interventions and oxygen
have only been able to recruit a limited number of
patients [7-10,13].
The purpose of this double blind, crossover study was
to assess the efficacy of morphine, compared to placebo,
on the intensity of dyspnea and its effect on respiratory
function in elderly patients with advanced cancer.
Patients and methods
Population and treatment
Ten patients with dyspnea due to advanced cancer were considered for
inclusion in this study. In all cases, patients scored within normal
limits in the mini-mental state examination [II]. Other inclusion
criteria were the absence of brain tumor and of acute incapacitating
respiratory decompensation. Nine patients gave their informed con-
sent. Seven opioid-naive patients were randomized to 5 mg subcuta-
neous morphine or placebo on day 1. Two patients were already
receiving oral morphine for analgesia. They were studied at their
regular morphine dosing and received the regular oral dose with, in
addition, half of the oral dose as a subcutaneous injection of mor-
phine, or placebo (in summary these two patients received at that
moment their usual 7.5 mg orally and either 3.75 mg morphine or
placebo subcutaneously). This double dose was given to overcome the
potential tolerance. Twenty-four hours later, the treatments were
crossed over, and the patients who had received morphine were given
placebo and vice versa.
Analysis of outcome
The main a priori endpoint of this study was the subjective intensity of
dyspnea according to the visual analog scale (VAS, modified by the
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Table 1. Difference in dyspnea (VAS and Borg scale) (mean ± SD).
Time
To
T45
Mean difference
VAS
Placebo
50.6 ± 18
51.1 ± 15
0.6 ±7.7
Morphine
57.8 ±16
32.8 ± 15
-25.0 ± IOa
Borg
Placebo
3.89+ 1
3.77 ± 1
-0.10 + 0
.8
.85
.3
Morphine
3.66±0 9
2.44 ± 1.1
-1.20 ± 1.2"
1
 P < 0.01.
'/» = 0.03.
addition of a numbered scale) and the Borg ordinal scale [12] deter-
mined forty five minutes after the injection of morphine or placebo.
The scales were also applied at other time points between 0 and 4
hours after dosing. Other measurements included VAS for pain,
somnolence and anxiety. The respiratory effort was determined using a
six-point score based on respiratory frequency, presence of cyanosis,
and utilization of accessory respiratory muscles (I: respiratory fre-
quency < 20/min; 2: respiratory frequency between 20 and 25/min; 3:
respiratory frequency between 26 and 30/min; 4: respiratory frequency
>30/min; +1: presence of cyanosis; +1: use of accessory respiratory
muscles). These scores were developed for clinical trials evaluating the
treatment of dyspnea [7] In addition, respiratory frequency and trans-
cutaneous pulsoxymetry were recorded.
All assessments took place before the subcutaneous injection (To)
and 45 minutes later (T4S) In addition, dyspnea, pain, anxiety and
somnolence were assessed by VAS every 15 minutes for two hours and
every hour up to four hours after injection. The mini-mental state
examination was repeated two hours after injection.
Ethical considerations
The study was approved by the Ethics Committee of the University
Hospital of Geneve.
Statistical methods
The study endpoints were compared under each treatment using an
analysis of variance for repeated measures, taking into account the
baseline response level at To. When more than two measurements were
performed, post-dosing results were compared to baseline using the
least significant differences test Period and carry-over effects were
explored using a similar approach.
Results
Sociodemographic and medical variables
During the nine-month study period, ten eligible pa-
tients were identified in a 120 beds geriatric hospital.
Nine patients agreed to participate. Their mean age was
73 years (66-83 years), four patients were female. The
main cause of dyspnea was primary or metastatic lung
involvement as a consequence of lung cancer (seven
cases), breast cancer (one case) and bladder cancer (one
case). Additional complicating factors included a history
of COPD (five cases), congestive heart failure (five cases),
carcinomatous lymphangitis (two cases), bilateral pleural
effusion (two cases), and pneumonia (one case). Seven
patients were on no opioid medication, and two received
oral morphine for analgesia at a dose of 7.5 mg every
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Figure 1. Dyspnea (VAS) at To and T45 after placebo and morphine.
Individual results. Closed symbols, placebo-morphine sequence. Open
symbols: morphine-placebo sequence. Squares: patients previously on
oral morphine.
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Figure 2. Intensity of dyspnea after morphine and placebo (VAS 0-100
mm) means ± SEM. Difference vs. baseline: * P < 0.05; ** P < 0.0I.
four hours. Mean survival after the study was 65 days
(median 30 days, 6-362 days).
Effects of morphine on dyspnea
Table 1 summarizes the difference in subjective dyspnea
intensity between To and T45, measured both by VAS
and the Borg ordinal scale. According to both measure-
ments, morphine was significantly better than placebo
for relieving dyspnea {P < 0.01, resp. P = 0.03). These
results are summarized in Figure 1. Neither period nor
carry-over effects were detected. Figure 2 shows that
morphine decreased significantly the intensity of dyspnea
from 15 minutes up to 180 minutes after dosing, while
placebo had no significant effect during the whole obser-
vation period.
Effects of morphine on other variables
The Table 2 summarizes the results observed in the other
variables between Tn and T45. A significant improve-
ment was observed in both respiratory effort score
(P = 0.05) and respiratory rate (P = 0.02) after morphine
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Table 2. Difference in other variables.
Variables Difference T0-T45
Placebo Morphine /'-value
Pain (VAS: 0-100 mm) -7.2 ± 22 -9.4 ± 14 0.82
Somnolence (VAS: 0-100 mm) -10.6 ±14 -7.8 ±21 0.78
Anxiety (VAS: 0-100 mm) -13.9 ±21 -13.3 ±17 0 95
Respiratory effort score (1-6) 0.1 ±0.6 -0.4 ± 0.7 0.05
Respiratory rate (breath/min) 0 ± 1.7 - 2 ± 2.2 0.02
Oxygen saturation (%) - 0 8 ±1.3 0 ± 1.5 0.31
as compared to placebo. There were no other significant
differences.
Side effects
Mini-mental state examinations were normal in all
patients at To and T12o- No patients reported any side
effects after the administration of placebo. After the
administration of morphine, one patient reported nausea
and vomiting (T120), one nausea (T^o), and one somno-
lence (T60) and nausea (T105). The symptoms were tran-
sient, and in only subject nausea and vomiting required
treatment.
Discussion
In this double blind, cross over study, morphine worked
significantly better than placebo in reducing the inten-
sity of dyspnea in patients with advanced cancer.
Although a total of 20 patients were forseen for this
study, only 9 patients were included in nine months. For
logistic reasons the study needed to be closed at that
point. Pharmacological studies of cancer patients with
dyspnea are extremely difficult to conduct. Unlike pa-
tients with heart failure or COPD, cancer patients can
rarely be submitted to standard exercise on a bicycle
or treadmill, to produce a controlled level of dyspnea
amenable to pharmacological modulation. In addition,
cancer dyspnea tends to vary dramatically along time, is
frequently accompanied by other devastating symptoms
like pain or delirium, and is associated with a short
survival. Patients with severe dyspnea may be exces-
sively distressed or cognitively impaired and therefore
unable to participate in clinical trials. These reasons
explain that the recruitment of cancer patients with
dyspnea in pharmacological studies has regulary been
found extremely difficult [7-9, 13].
Our results confirm those of the only controlled study
using morphine injections for cancer dyspnea [8]. How-
ever, Bruera et al. found in a previous uncontrolled
report that the duration of dyspnea relief after morphine
injection was much shorter than the duration of analgesia
in a group of patients with cancer pain and dyspnea [7].
Our study focused on a population in which the majority
of patients had no pain. In addition, the assessment in
our study was done under double-blind conditions,
while the observation from Bruera and al. was con-
ducted on a open basis. Our results and those of a recent
randomized continuous sequential clinical trial [9] sug-
gest that the duration of dyspnea relief after morphine
injection may be longer than initially reported and
perhaps as long as the duration of analgesia induced by
this drug. This has important implications for the pre-
scription of morphine for cancer dyspnea. Another pos-
sible explanation for this finding is that our patients were
on average ten years older than those of Bruera et al.,
and morphine elimination may have been slower. This
point needs to be further investigated in future studies.
Several questions remain open with regard to the
mode of action of opioids on dyspnea. Our results
(Table 2) indicate that the beneficial symptomatic effect
of morphine is not related to anxiolytic or sedative
actions. This is consistent with the previously reported
lack of correlation between intensity of anxiety and
dyspnea [14]. Accordingly, other studies showed limited
or no benefit of benzodiazepines in the management of
dyspnea associated with cancer and COPD [4-6]. Our
results are in agreement with those of Bruera et al. [8],
showing that the relief of dyspnea in elderly cancer
patients is not associated with a marked respiratory
depression, as indicated by the lack of differences in
oxygen saturation. Although the changes in both respi-
ratory rate and respiratory effort score are limited, these
findings suggest that the the symptomatic efficacy of
morphine could be explained in part by a decrease in
respiratory rate and effort (Table 2). Future studies
should attempt to better characterize the action of mor-
phine on these objective variables. Another mode of
action may rely on a decrease in cardiac pre-load in
patients with congestive heart failure [15, 16]. However,
this action cannot account on its own for all the effects
of morphine, since different studies have demonstrated a
beneficial effect on dyspnea in patients without cardiac
failure [17-20]. Morphine could also modify the central
perception of dyspnea, as it alters the perception of pain
[19]. Some authors report a decreased oxygen consump-
tion [17, 20], but these results have not been confirmed
by others [19]. Finally, the hypothesis of an ameliorated
pulmonary function has not been confirmed [17, 19].
Our results suggest that intermittent injections of
morphine (5 mg subcutaneously) can be used safely for
the symptomatic relief of cancer dyspnea, even in se-
verely affected patients, without significantly increasing
somnolence, at least on the start term. However, numer-
ous questions remain open with regard to the practical
utilization of opioids, in particular the optimal drug
dose, frequency and modalities of administration (e.g.,
regular versus as needed administration? place of slow
release opioids? suitability of other opioids than mor-
phine?). Only one trial has compared the efficacy of two
different doses of morphine on dyspnea. This study,
conducted in dyspneic patients already receiving mor-
phine for analgesia, suggest that supplemental doses of
morphine reaching of only one-quarter of the regular
four-hourly dose may suffice to reduce dyspnea [9].
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While our findings as well as other controlled and
uncontrolled reports suggest that opioids are effective in
the relief of dyspnea in both cancer and COPD patients
[7-9, 13, 17-20], benzodiazepines continue to be the
most widely recommended and used drugs in these
conditions, in spite of limited evidence of efficacy [4, 5].
Our results, though limited, could contribute to a wider
use of morphine to alleviate cancer-related dyspnea.
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